Quick Answer
Disc Medicine, Inc. reported Cash And Cash Equivalents At Carrying Value of $91.15 million for the year ending 2025.
- Disc Medicine, Inc. showed a decrease of -52.6% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Disc Medicine, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $0.00 | Q3 2020: $1.44 million | Q1 2021: $184.99 million | Q2 2021: $167.48 million | Q3 2021: $150.07 million | Q1 2022: $119.06 million | Q2 2022: $108.66 million | Q3 2022: $101.74 million | Q1 2023: $236.42 million | Q2 2023: $377.60 million | Q3 2023: $370.54 million | Q1 2024: $342.62 million | Q2 2024: $280.66 million | Q3 2024: $192.64 million | Q1 2025: $122.68 million | Q2 2025: $127.34 million | Q3 2025: $140.66 million.
- Over the full 6 years of available data (2020 to 2025), Disc Medicine, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 1,924.1%.
- Historical annual values: Fiscal year 2025: $91.15 million | Fiscal year 2024: $192.43 million | Fiscal year 2023: $360.38 million | Fiscal year 2022: $194.61 million | Fiscal year 2021: $88.04 million | Fiscal year 2020: $4.50 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: